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Abstract
BACKGROUND—The health benefits of diet and exercise interventions for cancer survivors are 
well documented. However, little is known regarding demographic and medical predictors of 
survivors’ willingness to participate in diet and exercise intervention trials, study enrollment, 
intervention adherence, and study completion. To assist in interpreting the generalizability of trial 
findings as well as to improve the design of future trials, we examined predictors of these process 
measures.
METHODS—An integrative data analysis was performed on data from three of the largest home-
based diet and exercise intervention trials for cancer survivors (N=23,841). Demographic and 
medical factors (i.e., gender, race, age, time since diagnosis, and cancer type) were examined as 
predictors of willingness to participate, study enrollment, intervention adherence, and study 
completion in the pooled sample. A 99% confidence interval was used to determine statistical 
significance.
RESULTS—Across trials, 11.1% of contacted survivors were willing to participate and 5.7% 
were eligible and enrolled. Among enrollees, 53.4% demonstrated ≥75% adherence to the 
intervention and 91.1% completed the study. Race (Caucasian vs. others), age, time since 
diagnosis, and cancer type predicted survivors’ willingness to participate (p-values<.01). All 
examined predictors were associated with the likelihood of study enrollment (p-values<.01). No 
significant predictors of intervention adherence or study completion were found among study 
enrollees (p-values≥.01).
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CONCLUSIONS—Cancer survivors’ demographic and medical characteristics predicted their 
interest and participation in diet and exercise intervention trials. These findings have implications 
for the generalizability of results and can help guide procedures used in future trials to enhance 
patient representation.
Keywords
neoplasms; survivorship; intervention studies; adherence; diet; exercise
Cancer survivors are at increased risk for secondary cancers, medical comorbidities, 
accelerated functional decline, and poor health-related quality of life (HRQOL).1–8 A 
healthy diet and regular exercise have been found to reduce disease risk and physical decline 
in this population.2, 9, 10 However, similar to adults in the general population, many cancer 
survivors do not meet national dietary and exercise guidelines.1–3
Lifestyle intervention trials have been conducted to improve the dietary and exercise 
behaviors of cancer survivors.11 In randomized controlled trials (RCTs), combined diet and 
exercise interventions have resulted in improved diet quality, increased exercise, better 
physical functioning, decreased obesity, and increased HRQOL among recently diagnosed 
and long-term cancer survivors.12, 13
Although the health benefits of diet and exercise interventions for cancer survivors are well 
documented, little is known regarding demographic and medical predictors of survivors’ 
willingness to participate in intervention trials, study enrollment, adherence to diet and 
exercise interventions, and study completion.14–16 CONSORT standards for reporting trial 
methods17 do not require that authors report characteristics of individuals who do not: 1) 
agree to an eligibility assessment; 2) enroll in the study; 3) adhere to the intervention; and 4) 
complete the study. Although some lifestyle intervention trials for cancer survivors have 
reported demographic and medical predictors of adherence,14, 16 data on upstream events, 
such as willingness to participate in trials, are often not collected. Subsequently, studies 
have not combined data across trials for these analyses–a necessary step because the 
representation of participants from low base rate groups (e.g., racial minorities) is often too 
small to justify analysis. Thus, the goal of the present study was to examine demographic 
(i.e., gender, race, age) and medical (i.e., time since diagnosis, cancer type) predictors of 
willingness to participate in lifestyle intervention trials, study enrollment, intervention 
adherence, and study completion using pooled data from three large diet plus exercise RCTs 
for breast, colorectal, and prostate cancer survivors. The outcome of this analysis has 
implications for the generalizability of trial findings. Furthermore, if certain demographic or 
medical subgroups are less likely to participate in different aspects of research, investigators 
may modify these aspects to enhance their appeal or effectiveness for these groups. In this 
analysis, we focused specifically on Project LEAD (Leading the Way in Exercise And 
Diet),18 FRESH START,19 and RENEW (Reach-out to EnhaNcE Wellness)20 because all 
three of these large trials relied heavily on population-based approaches to recruit 
participants through state cancer registries or multiple institutions, thus reducing potential 
bias involved with single institution studies. Moreover, all of the interventions were 
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delivered and evaluated using home-based strategies; thus the barriers of time and travel 
were similarly reduced in each of these trials.
Materials and Methods
Samples and Procedure
Data from three home-based diet and exercise RCTs for cancer survivors (i.e., Project 
LEAD,18 FRESH START,19 and RENEW20) were used in the current analyses. Complete 
descriptions of trial methods have been published.18–20 Institutional review boards approved 
all trial procedures, which are summarized in Table 1. All trials relied on state cancer 
registries or medical records of multiple institutions to identify potential participants; other 
commonalities included a home-based approach for delivering and evaluating the 
intervention, and similar means of approaching potential participants, i.e., through a mailed 
letter of invitation, which included consent forms, a return envelope, and a screening 
questionnaire designed to exclude individuals who (1) routinely exercised (≥150 minutes per 
week of moderate to vigorous physical activity) or adhered to a healthy diet (≥5 fruit and 
vegetable servings per day); (2) had progressive cancer or additional primary tumors; or (3) 
had conditions precluding full participation in the intervention. Sample characteristics and 
statistics regarding recruitment, enrollment, completion, and adherence within and across 
trials appear in Table 2.
Study Variables
The four study outcomes were dichotomous variables. Survivors who completed and 
returned the eligibility screener and consent form via postal mail were considered willing to 
participate. Survivors who were willing to participate and eligible were considered enrolled. 
Participants who demonstrated at least 75% adherence to the intervention (i.e., completed 
≥75% of telephone counseling sessions for the RENEW or Project LEAD studies or returned 
≥75% of their mailed update cards for FRESH START) were considered adherent. 
Adherence was computed for intervention groups only, including the delayed intervention 
comparison group in RENEW. Participants who remained enrolled in the study after the 
intervention and who completed follow-ups were considered to have completed the study.
Baseline predictors of study outcomes were gender, race (white versus racial minority), age, 
years since diagnosis, and cancer type.
Statistical Analyses
Integrative data analysis of the three trials was used to examine predictors of willingness to 
participate, study enrollment, intervention adherence, and study completion. Integrative data 
analysis involves pooling original data sets for simultaneous analysis of multiple studies.21 
Research suggests that analysis of primary data is superior to an analysis of study-level 
summary data (i.e., meta-analysis) when studying relationships between patient-level 
characteristics and trial outcomes.22, 23 Advantages of analyzing primary data include 
increased statistical power and sample heterogeneity.22–24 A fixed-effects model-based 
procedure was employed in this study rather than a random-effects model because of the 
small number of studies.21 Study membership was included as a covariate to control for 
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differences in eligibility criteria across studies that affected the probability of an individual 
being sampled.
After pooling the data sets, univariate logistic regression analyses were run in SPSS to 
examine relationships between each predictor and outcome, controlling for study 
membership (i.e., Project LEAD, FRESH START, or RENEW). Relations of time since 
diagnosis and cancer type to each outcome were examined twice: once with the RENEW 
trial sample only and once with the Project LEAD and FRESH START study samples 
combined. These analyses were run separately because these variables differed between 
RENEW and other studies (see Table 1). For RENEW analyses, two orthogonal contrast 
codes for cancer type were included in the same analysis. Across trials, only data from study 
enrollees were included when examining intervention adherence and study completion. To 
reduce Type I error, a 99% confidence interval was used to determine statistical 
significance.
Results
Sample characteristics are shown in Table 2. Data from 23,841 survivors were included in 
analyses.
Predictors of willingness to participate
Predictors of survivors’ willingness to participate in the studies appear in Table 3. White 
survivors were more likely to show interest than racial minority survivors. In addition, for 
every 1-year increase in age, there was a 5% decrease in survivors’ likelihood of showing 
interest in the study. Women were more likely to show interest than men, though this result 
fell short of significance. Furthermore, time since diagnosis was not significantly related to 
survivors’ willingness to participate in Project LEAD and FRESH START; however, in the 
RENEW trial, for every 1-year increase in time since diagnosis, there was a 5% decrease in 
survivors’ likelihood of showing interest in the study. Additionally, cancer type was not a 
significant predictor of survivors’ willingness to participate in Project LEAD and FRESH 
START. However, in the RENEW trial, breast and prostate cancer survivors were more 
willing to participate than colorectal cancer survivors, and breast cancer survivors were 
more willing to participate than prostate cancer survivors.
Predictors of study enrollment
Predictors of enrollment status also were examined (see Table 3). Among all individuals 
approached for study participation, women and white survivors were more likely to be 
eligible and subsequently enroll than men or racial minorities. Furthermore, for every 1-year 
increase in age, there was a 5% decrease in survivors’ likelihood of enrolling. Similar to 
interest in the study, enrollment was not associated with time since diagnosis in Project 
LEAD or FRESH START; however, in the RENEW trial, for every 1-year increase in time 
since diagnosis, survivors’ likelihood of being eligible and subsequently enrolling decreased 
by 7%. Additionally, in the RENEW trial, breast and prostate cancer survivors were more 
likely to enroll than colorectal cancer survivors and, in all trials, breast cancer survivors 
were more likely to enroll than prostate cancer survivors.
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Predictors of intervention adherence
Predictors of intervention adherence were examined among study enrollees only (see Table 
3). None of the demographic and medical variables predicted survivors’ likelihood of 
adhering to the intervention.
Predictors of study completion
Predictors of study completion also were examined among study enrollees only (see Table 
3). There were no significant predictors of survivors’ likelihood of completing the study.
Discussion
When approached for participation in diet and exercise intervention trials, cancer survivors’ 
background characteristics predicted their likelihood of expressing interest in participation 
and enrolling in the study. Given that less than 2% of clinical studies report demographic 
characteristics of individuals who decline study participation,25 this is one of the first reports 
regarding protocol implementation. In our analysis of over 23,000 cancer survivors, race, 
gender, age, time since diagnosis, and cancer type predicted survivors’ likelihood of 
expressing interest in trial participation or enrolling in the trial. Many investigators have 
reported low enrollment of racial minorities in clinical trials by comparing the racial 
composition of clinical trial cohorts with population-based norms,26, 27 rather than 
performing statistical comparisons. Given historical discrimination and unethical treatment 
of minority groups in research trials,28–30 distrust of research and medicine might explain 
minority survivors’ lack of interest in participation. Furthermore, culture-specific barriers 
and those related to socioeconomic status, such as low literacy, inflexible work schedules, or 
childcare demands, can reduce minority participation.31
Regarding participant gender, women were more likely to enroll in the trials. Women also 
tended to show greater interest in trial participation, but this finding fell short of statistical 
significance. Women’s higher enrollment in diet and exercise intervention trials relative to 
men is unsurprising given their greater use of healthcare services in general.32 Similarly, 
breast cancer survivors were more likely to enroll in Project LEAD and FRESH START 
than prostate patients, but there was no statistically significant difference in interest in 
participation. Because trial enrollment was confounded with eligibility status in the 
examined studies, another explanation for the gender/cancer type difference is the higher 
prevalence of certain health conditions, such as cardiovascular disease, among men,33 which 
may preclude participation in unsupervised exercise. Moreover, men tend to be more 
physically active,34 as well as less likely to report deficits in physical functioning35 and thus 
were screened-out of two of the three trials analyzed.
Regarding cancer type, in the RENEW trial, breast and prostate cancer survivors were more 
likely to show interest and subsequently enroll than colorectal cancer survivors. Differences 
in physical symptoms by cancer type that affect lifestyle practices provide one potential 
explanation for these findings.
Age and time since diagnosis also were found to predict survivors’ willingness to participate 
in the studies and subsequent enrollment. Specifically, older survivors were less likely to 
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show interest in the studies and enroll. Low enrollment of older adults is commonly 
reported; however, it is often attributed to physicians’ age bias27, 36 rather than higher rates 
of refusal by older adults, as were found in this study. Potential explanations for these age 
differences include older adults’ perceived barriers to exercise, such as fear of falling and 
the belief that their health conditions preclude exercise.37, 38 Additionally, one study of 
older adults suggested that they may prefer learning about studies via face-to-face contact 
rather than methods used in the current trials (i.e., telephone and print materials).39 Age was 
positively correlated with time since diagnosis in the RENEW study, which may help 
explain the lower likelihood of showing interest in the study and enrolling among survivors 
farther out from diagnosis. Alternatively, survivors may perceive less benefit from lifestyle 
changes as their illness becomes less salient over time; however, all survivors approached 
for the RENEW trial were long-term survivors (≥5 years post-diagnosis). In contrast, time 
since diagnosis did not predict interest in study participation and enrollment in trials of more 
recently diagnosed survivors (i.e., FRESH START and Project LEAD). However, given that 
the period from diagnosis to contact was fairly compressed, it is likely that insufficient 
variation in time since diagnosis in these two trials precluded the ability to observe 
significant differences.
None of the examined demographic or medical factors predicted intervention adherence or 
study completion, suggesting that, once survivors are enrolled, engagement in diet and 
exercise interventions does not differ by these factors. Of note, in all of the analyzed studies, 
survivors had to return a screener by mail in order to enroll in the trial. As a result, 
recruitment rates were quite low (see Table 2), and study enrollees may have had greater 
motivation for health behavior change than the typical cancer survivor, leading to high 
adherence and retention rates across demographic and medical subgroups.
Although this integrative analysis has several strengths, e.g., a large and diverse sample, a 
population-based approach, and similar methods across the combined studies, limitations 
should be noted. Our analyses examined only five predictors; therefore, other survivor 
characteristics that might impact the likelihood of participation in all phases of lifestyle 
intervention trials warrant examination. In addition, our analyses focused on the only three 
home-based diet and exercise intervention trials for cancer survivors, all of which used 
recruitment mailings; thus, the findings may not generalize to survivors approached for trials 
using more active recruitment strategies or testing other types of lifestyle interventions. 
Furthermore, all three trials were conducted by a single research group, and participants 
were primarily from the Southern U.S. Findings warrant replication across research groups 
and geographical areas. Finally, reasons for survivors’ non-participation in the trials were 
not collected and would enhance our understanding of barriers to trial enrollment.
Results point to the need to increase representation of racial minorities and older adults in 
future diet and exercise intervention trials with cancer survivors. Regarding minority 
participation, researchers may partner with “cultural insiders” from community-based 
organizations, approaches that have increased minority enrollment in other types of health 
research.29, 30 Within these organizations, passive recruitment strategies (e.g., disseminating 
information and allowing prospective participants to contact study staff) result in higher 
recruitment rates than proactive strategies (e.g., approaching patients) and also are far less 
Adams et al. Page 6
Cancer. Author manuscript; available in PMC 2016 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
expensive.30, 40 In addition, clinicians and researchers should be sensitive to cultural 
differences when referring patients to trials.
Regarding older adults’ trial participation, research suggests that referral and 
recommendation by clinicians might yield higher recruitment rates.39 Additionally, older 
adults prefer face-to-face contact rather than recruitment via telephone or flyers.39, 41 During 
recruitment, clinicians and researchers may probe for age-specific barriers to trial 
participation. Determining the most effective methods to engage older cancer survivors in 
lifestyle intervention trials is critical, as they comprise the largest group of cancer survivors 
and are at greater risk of poor health outcomes than the general older adult population. 4–8
In addition to researching strategies to reduce racial and age differences in trial participation, 
publication of sample characteristics at all phases of lifestyle and other intervention trials is 
needed to better understand the degree to which findings are generalizable and to inform the 
design of future trials. Determining who participates in clinical trials and who does not is the 
first step in designing interventions with high reach and the potential for reducing health 
disparities.
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r d
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r c
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l c
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I b
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 re
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 m
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 d
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w
ee
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R
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f m
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t m
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ls 
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ra
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m
en
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ar
y 
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d 
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ev
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6 
w
ee
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o
n
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s
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oo
k;
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ilo
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tte
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to
m
at
ed
 te
le
ph
on
e 
pr
om
pt
s a
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fte
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 3
0-
m
in
ut
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le
ph
on
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co
un
se
lin
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se
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io
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on
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r d
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ry
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er
ci
se
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oa
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-m
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 in
te
rv
en
tio
n 
pe
rio
d
Co
nt
ro
l a
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N
on
-p
er
so
na
liz
ed
 w
or
kb
oo
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 2
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 3
0-
m
in
ut
e 
te
le
ph
on
e 
co
un
se
lin
g 
se
ss
io
ns
 e
ve
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 w
ee
ks
 fo
r 6
 
m
o
n
th
s a
bo
ut
 h
ea
lth
 p
ro
m
ot
io
n 
to
pi
cs
 u
nr
el
at
ed
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di
et
 a
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 e
xe
rc
ise
R
ec
ei
pt
 o
f n
on
-ta
ilo
re
d 
m
ai
le
d 
pr
in
t m
at
er
ia
ls 
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he
al
th
 p
ro
m
ot
io
n 
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pi
cs
 e
ve
ry
 6
 w
ee
ks
 fo
r 1
0 
m
o
n
th
s
D
el
ay
ed
 in
te
rv
en
tio
n 
fo
llo
w
in
g 
co
m
pl
et
io
n 
of
 1
-y
ea
r 
fo
llo
w
-u
p
In
te
rv
en
tio
n 
go
al
s
Im
pr
ov
ed
 fu
nc
tio
na
l s
ta
tu
s; 
in
cr
ea
se
d 
qu
al
ity
 o
f 
lif
e;
 b
et
te
r d
ie
t q
ua
lit
y 
an
d 
ph
ys
ic
al
 a
ct
iv
ity
 le
ve
l
≥ 
30
 m
in
ut
es
 o
f e
xe
rc
ise
 p
er
 d
ay
 a
t l
ea
st 
5 
da
ys
 a 
w
ee
k;
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 5
 se
rv
in
gs
 o
f f
ru
its
 an
d 
ve
ge
ta
bl
es
 p
er
 d
ay
; 
<
 3
0%
 o
f c
al
or
ie
s f
ro
m
 fa
t
≥ 
15
 m
in
ut
es
 o
f s
tre
ng
th
 ex
er
ci
se
 ev
er
y 
ot
he
r d
ay
; ≥
 3
0 
m
in
ut
es
 o
f e
nd
ur
an
ce
 e
xe
rc
ise
 p
er
 d
ay
; 7
 se
rv
in
gs
 o
f f
ru
it 
an
d 
ve
ge
ta
bl
es
 p
er
 d
ay
 fo
r w
om
en
 a
nd
 9
 se
rv
in
gs
 o
f f
ru
it 
an
d 
ve
ge
ta
bl
es
 p
er
 d
ay
 fo
r m
en
; <
 1
0%
 to
ta
l c
al
or
ie
s f
ro
m
 
sa
tu
ra
te
d 
fa
t; 
ap
pr
ox
im
at
el
y 
10
%
 w
ei
gh
t l
os
s
Ti
m
in
g 
of
 fo
llo
w
-u
p 
in
te
rv
ie
w
s
6 
an
d 
12
 m
on
th
s p
os
t-b
as
el
in
e
1 
an
d 
2 
ye
ar
s p
os
t-b
as
el
in
e
1 
an
d 
2 
ye
ar
s p
os
t-b
as
el
in
e
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rti
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 c
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pl
et
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 in
te
rv
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tio
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w
er
e c
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sid
er
ed
 to
 b
e a
dh
er
en
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Fo
r t
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 in
te
rv
en
tio
n 
ad
he
re
nc
e o
ut
co
m
e, 
da
ta
 w
er
e o
nl
y 
in
cl
ud
ed
 fr
om
 p
ar
tic
ip
an
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re
ce
iv
in
g 
th
e i
nt
er
ve
nt
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co
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di
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cl
ud
in
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de
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en
tio
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ts 
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ho
 re
m
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ne
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en
ro
lle
d 
in
 th
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stu
dy
 a
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 e
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 o
f t
he
 in
te
rv
en
tio
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pe
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d 
an
d 
co
m
pl
et
ed
 fo
llo
w
-u
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se
ss
m
en
ts 
w
er
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co
ns
id
er
ed
 to
 h
av
e 
co
m
pl
et
ed
 th
e 
stu
dy
.
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 c
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 re
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d r
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 c
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in
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en
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n 
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dy
 c
om
pl
et
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om
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, d
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a 
w
er
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cl
ud
ed
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rti
ci
pa
nt
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ho
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 th
e 
stu
di
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. F
or
 th
e 
in
te
rv
en
tio
n 
ad
he
re
nc
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ou
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om
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 d
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a 
w
er
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ed
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 p
ar
tic
ip
an
ts 
re
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iv
in
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th
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in
te
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en
tio
n 
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iti
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di
ng
 th
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de
la
ye
d 
in
te
rv
en
tio
n 
in
 
R
EN
EW
. P
ar
tic
ip
an
ts 
w
ho
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dh
er
ed
 to
 th
e 
in
te
rv
en
tio
n 
co
m
pl
et
ed
 ≥
75
%
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f i
nt
er
ve
nt
io
n 
re
qu
ire
m
en
ts.
 P
ar
tic
ip
an
ts 
w
ho
 co
m
pl
et
ed
 th
e s
tu
dy
 w
er
e e
nr
ol
le
d 
in
 th
e s
tu
dy
 at
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e e
nd
 o
f t
he
 in
te
rv
en
tio
n 
pe
rio
d 
an
d 
co
m
pl
et
ed
 fo
llo
w
-u
p 
as
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ss
m
en
ts.
 O
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od
ds
 ra
tio
; C
I—
co
nf
id
en
ce
 in
te
rv
al
. A
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 co
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 in
te
rv
al
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d 
to
 d
et
er
m
in
e s
ta
tis
tic
al
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gn
ifi
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e.
a
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de
d 
(m
ale
 −1
, fe
ma
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+1
).
b C
od
ed
 (n
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-w
hit
e −
1, 
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ite
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).
c D
at
a 
fro
m
 P
ro
jec
t L
EA
D 
an
d F
RE
SH
 ST
AR
T o
nly
. S
tud
y m
em
be
rsh
ip 
wa
s i
nc
lud
ed
 as
 a 
co
va
ria
te.
d D
at
a 
fro
m
 R
EN
EW
 o
nl
y.
e D
at
a 
fro
m
 P
ro
jec
t L
EA
D 
an
d F
RE
SH
 ST
AR
T o
nly
. C
od
ed
 (P
ros
tat
e c
an
cer
 −1
, B
rea
st 
can
cer
 +1
).
f D
at
a 
fro
m
 R
EN
EW
 o
nl
y.
 C
on
tra
st 
co
de
 re
po
rte
d 
(C
olo
rec
tal
 ca
nc
er 
−2
, P
ros
tat
e a
nd
 B
rea
st 
ca
nc
er 
+1
).
g D
at
a 
fro
m
 R
EN
EW
 o
nl
y.
 C
on
tra
st 
co
de
 re
po
rte
d 
(C
olo
rec
tal
 ca
nc
er 
0, 
Pr
os
tat
e −
1, 
Br
ea
st 
+1
).
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